Discover Future Pharma Growth Opportunity in East & West Africa

Attend this webinar to discover:

·Insight from BRIC healthcare leaders as they share field experiences and best practices gathered through hundreds of successful cases
·Common obstacles international companies must overcome in these regions
·How to exploit the hidden potential of BRIC countries
·Tactics to adjust strategy to successfully penetrate BRIC markets
·The top 10 technologies and products expected to drive growth in these regions

Advances in the understanding of the behavior and function of biological systems are dependent on the study of cells and tissues. An essential tool in this research is the use of in vitro cell culture. Many variables contribute to providing a physiological environment for the cell in the laboratory, a few examples include cell source, isolation techniques, growth conditions such as matrix proteins and soluble factors, and cell age. Basic laboratory practices are sometimes overlooked as a source of discrepancy in data; however the application of fastidious and reproducible technique can reduce cell culture as a source of data variation. As specialized techniques have been developed to modulate cells and tissues in vitro, the importance of reproducible data has become paramount. In this presentation, we will identify and discuss basic principles of in vitro mammalian cell culture that influence the quality of experimental results.

Attend this webinar to discover:

•Evaluate market potential for basic and advanced medical imaging modalities
•Learn about important market characteristics and trends
•Identify opportunities for growth in medical imaging equipment markets within each region of the world
•Consider factors affecting market growth internationally

As the healthcare industry across APAC moves toward digitization, electronic health information exchange becomes a stepping stone to success. Governments, non-profit entities and the private sector are aggressively investing in Electronic Medical Record (EMR) and Electronic Health Record (EHR) systems. This Frost & Sullivan briefing presents a comprehensive analysis of the EMR and EHR markets in APAC, with special focus on emerging opportunities in the region.

Why You Should Attend:
- Learn about the rapidly developing EMR and EHR markets in APAC
- Understand key market drivers and restraints
- Identify leading market participants and their role in the competitive environment
- Recognize areas of growth within this space

In recent decades, the nasal and bronchial mucosa has become an established administration site for systemic as well as local drug delivery. For developing novel drugs intended for this route, reliable methods are needed for assessing the rate and extent of absorption across the nasal and bronchial epithelium. Epithelix has developed a novel in vitro cell model of the human airway epithelium named MucilAir™. MucilAir™ maintains the fully differentiated, morphologically and functionally, characteristics of the native tissues for more than one year. Using this system, the typical characteristics of the airway epithelium are observed (e.g. tight junctions, cilia beating, ciliated cells, basal cells, mucous cells, cytokine/chemokine/metalloproteinase release, active ion transport and CypP450s activity). Epithelia from several pathologies can be reconstructed (e.g. Asthma, Allergic Rhinitis, COPD, CF, etc.). Due to its unique long shelf-life, this model is used for studying the human respiratory diseases, and for testing the long-term/chronic effects of drugs candidates on respiratory tract. Several applications of MucilAir™ relevant to drug delivery, inhalation efficacy and toxicity assessment will be presented. For each application, specific examples of in vitro tests will be selected to highlight the Pros and Cons of using in vitro human airway epithelia for development of new drug candidates for respiratory diseases.

Glucuronidation is as a major pathway for the metabolism and elimination of drugs in humans. It is second only to P450 for the metabolic clearance of currently marketed drugs. The glucuronidation reaction is catalyzed by the Phase 2 enzyme UDP-glucuronosyltransferase (UGT), which like the P450s exists as a superfamily of enzymes with broad and overlapping substrate specificities. Identification of the UGT isoforms important for the glucuronidation of new chemical entities is essential for predicting and avoiding the risk of adverse reactions due to either drug-drug interactions or genetic polymorphisms. This webinar will provide an in depth overview of in vitro methods for studying UGT pathways. Important parameters for setting up UGT assays using tissue fractions and recombinant UGT enzymes will be discussed, as well as the methods and tools currently available for conducting UGT reaction phenotyping studies.

What is CAPPS? … short for Complex Abdominal -Pelvic Pain Syndrome, CAPPS is a syndrome of nonmalignant origin consisting of a complex of abdominal and pelvic symptoms that includes a variety of painful bowel, bladder, genital, reproductive, muscular and nerve dysfunctions lasting at least 3-6 months in duration.

Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) patients often have overlapping chronic conditions, including fibromyalgia, irritable bowel syndrome, vulvodynia, endometriosis, pudendal neuralgia, pain with sexual intimacy, pelvic floor dysfunction, obstructing adhesions, lichen sclerosis, and even TMJ, as well as psycho-social issues that often develop as a result of these difficult conditions.

Attempting to treat these disorders as separate entities is often a frustrating task for patients and practitioners alike. Although these conditions may start out separately, they may be better diagnosed, assessed and treated as essentially connected disorders of pain processing in the pelvic region — CAPPS.

In this webinar, Robert J. Echenberg, MD, FACOG, will discuss not only IC/PBS’s role in CAPPS, but also the multi-disciplinary and holistic approach that is needed in order to most effectively treat what most practitioners call “chronic pelvic pain (CPP). He will explain how IC/PBS should be considered as a “major player” in the broader context of “connecting the dots” in this family of all too common and debilitating conditions.

This ICA webinar is made possible with the generous support of Innovation Compounding.

This presentation seeks to highlight:
- Market projections for the global medical devices market
- Identification of market sectors and sub-sectors poised for expansion
- Discussion of key market opportunities in emerging markets
- Strategies for success in the new market paradigm

This briefing will investigate how regulations and hospital needs stimulate the EMR market in Latin America and will specially focus on how these regulations will potentially encourage the EMR implementation until 2017.

Why You Should Attend:
·Learn about the market dynamics of EMR in the region
·Identify the drivers and restraints impacting the EMR market for the next six years
·Discover business opportunities

Top Five Asia Pacific Growth Sectors:
•Medical Tourism: Driven by rising affluence and increasing demand for quality healthcare, medical tourism is one of the top growth sectors in APAC in the short to medium term.
•Outpatient Surgery: This is a lucrative business option that requires less investment, with more profitability.
•Specialty Hospitals: Due to increasing lifestyle diseases, such as diabetes and coronary heart disease, Asia Pacific is a large marketplace for specialty hospitals.
•Private Medical Insurance: The increasing cost of healthcare, coupled with low penetration rates of public insurance, creates an expansive market for private insurance companies. Consumer empowerment will also spike private medical insurance revenues.
•Healthcare IT: To remain competitive by increasing operational efficiency, clinical outcomes and financial profitability, private and public hospitals will invest extensively in installing, maintaining and upgrading IT capabilities.